Metagenomi Therapeutics, Inc. (MGX) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $4.00K; Additional Paid in CapitalUSD $474.10M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-122.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $4.00K; Additional Paid in CapitalUSD $471.75M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-44.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $4.00K; Additional Paid in CapitalUSD $469.20M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $260.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $4.00K; Additional Paid in CapitalUSD $466.41M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $371.00K.
Metagenomi Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $4.00K | $474.10M | $-122.00K | $-361.41M | $112.57M | 3 month · $2.27M |
| 2026-03-31 | $0.00 | $4.00K | $471.75M | $-44.00K | $-333.93M | $137.78M | 3 month · $2.55M |
| 2025-12-31 | $0.00 | $4.00K | $469.20M | $260.00K | $-310.87M | $158.60M | 12 month · $11.85M |
| 2025-09-30 | $0.00 | $4.00K | $466.41M | $371.00K | $-288.34M | $178.45M | 3 month · $3.01M |
| 2025-06-30 | $0.00 | $4.00K | $463.40M | $372.00K | $-267.95M | $195.83M | 3 month · $3.22M |
| 2025-03-31 | $0.00 | $4.00K | $460.07M | $621.00K | $-248.04M | $212.66M | 3 month · $2.93M |
| 2024-12-31 | $0.00 | $4.00K | $457.15M | $709.00K | $-223.00M | $234.86M | 12 month · $16.20M |
| 2024-09-30 | $0.00 | $4.00K | $453.73M | $1.64M | $-199.60M | $255.77M | 3 month · $3.22M |
| 2024-06-30 | $0.00 | $4.00K | $450.51M | $-265.00K | $-180.83M | $269.42M | 3 month · $4.51M |
| 2024-03-31 | $0.00 | $4.00K | $446.00M | $-278.00K | $-170.09M | $275.63M | 3 month · $5.06M |
| 2023-12-31 | $0.00 | $0.00 | $9.46M | $-97.00K | $-144.94M | $-135.58M | 12 month · $6.92M |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | $-119.02K | 3 month · $3.27K |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | $-102.54M | 3 month · $656.00K |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | $-90.01M | 3 month · $529.00K |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | $-74.43M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |